All Stories

  1. The future of pharmacogenetics in Parkinson's disease treatment
  2. SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria
  3. The dopamine transporter role in psychiatric phenotypes
  4. The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment
  5. GAD1gene polymorphisms are associated with hyperactivity in Attention-Deficit/Hyperactivity Disorder
  6. Variability of innate immune system genes in Native American populations-relationship with history and epidemiology
  7. LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study
  8. Association between HLA-DR4 haplotypes and tuberculin skin test response in the Aché population
  9. Glutamatergic copy number variants and their role in attention‐deficit/hyperactivity disorder
  10. A New Algorithm for Weekly Phenprocoumon Dose Variation in a Southern Brazilian Population: Role for CYP2C9, CYP3A4/5 and VKORC1 Genes Polymorphisms
  11. Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease
  12. Association study of GIT1 gene with attention‐deficit hyperactivity disorder in Brazilian children and adolescents